- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03027167
Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty (PDAS)
Outcomes Study to Determine the Incidence of Symptomatic DVT/PE in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty
Study Overview
Status
Intervention / Treatment
Detailed Description
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the most common complication occurring in association with knee and hip arthroplasty procedures due to an activation of the clotting cascade during bone and intramedullary canal preparation.DVT rates ranging from 4% to 15 % and PE rates ranging from 0.83% to 3% have been reported, with fatal PE rates reduced with the use of postoperative anticoagulation. The high risk of thromboembolic disease has led to recommendations that pharmacoprophylaxis be considered routinely. • The combination of short duration outpatient anticoagulation, early mobilization, and mechanical prophylaxis has recently been studied at our institution (Barnes-Jewish Hospital) and has been effective in prophylaxis against VTE. Current American College of Chest Physician (ACCP) guidelines recommend that a longer duration of outpatient anticoagulation following TKA / THA surgery may further reduce the risk of VTE.
Shorter patient hospitalizations and earlier discharge require an outpatient VTE prophylaxis regimen that is simple, effective, easy to monitor, predictable, and has a high patient compliance. Currently, "routine" risk patients receive a combination of ASA 325mg BID (twice daily) for a period of 6 weeks, and portable, mobile pneumatic compression devices (MCDs) for a period of 10 days post- surgery.The study is testing to see whether the use of ASA alone can be equally effective versus the use of ASA with MCDs in "routine" risk patients following total joint arthroplasty.Patients are enrolled fpr 6 months following surgery, and data collection occurs pre-surgery, 14 days after surgery, at the 4-8 wk visit and finally, at 6 months post surgery. We are evaluating the stated outcomes over this 6 month period.
Study Type
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All total knee arthroplasty (TKA), unicompartmental knee arthroplasty (UKA), total hip arthroplasty (THA), and surface replacement arthroplasty (SRA) patients age 18 or older and undergoing an elective primary or revision procedure will be eligible to participate in this study.
Exclusion Criteria:
Patients will be excluded if they are on chronic Coumadin therapy, require prolonged immobilization (i.e. cast/knee immobilizer; inability to be full weight-bearing and out of bed on postoperative day 1), and are scheduled to have multiple surgeries in close proximity to one another. Based on our institution's risk stratification protocol, all patients deemed "high risk" and meeting one of the following criteria will also be excluded as they would receive Coumadin for VTE prophylaxis:
- Patients will be excluded if they are on chronic Coumadin therapy
- History of DVT/PE
- Active Cancer
- Hypercoaguable States (Protein C, Protein S, Factor V Leiden, etc.)
- Family history of thrombosis -note: we may remove this criteria after further discussion
- Patients requiring prolonged immobilization (i.e. cast/knee immobilizer),
- Patients having multiple surgeries in close proximity to one another.
- Patients with known allergy or hypersensitivity to Aspirin or Platelet count < 60, 000
- Patients receiving bilateral joint replacement
Patients who consent to the study and cancel/do not have a surgery scheduled within six months of signing the consent form will not be included. immobilization (i.e. cast/knee immobilizer; inability to be full weight-bearing and out of bed on postoperative day 1), and are scheduled to have multiple surgeries in close proximity to one another. Based on our institution's risk stratification protocol, all patients deemed "high risk" and meeting one of the following criteria will also be excluded as they would receive Coumadin for VTE prophylaxis:
- Patients will be excluded if they are on chronic Coumadin therapy
- History of DVT/PE
- Active Cancer
- Hypercoaguable States (Protein C, Protein S, Factor V Leiden, etc.)
- Family history of thrombosis -note: we may remove this criteria after further discussion
- Patients requiring prolonged immobilization (i.e. cast/knee immobilizer),
- Patients having multiple surgeries in close proximity to one another.
- Patients with known allergy or hypersensitivity to Aspirin or Platelet count < 60, 000
- Patients receiving bilateral joint replacement
Patients who consent to the study and cancel/do not have a surgery scheduled within six months of signing the consent form will not be included. (Note: The surgery does not have to occur within six months of signing the consent form but must be scheduled/re-scheduled within six months of signing the consent form.) If these patients decide to schedule surgery after the six months has passed, they will be re-consented at the time they schedule surgery.
Patients who are not willing to participate will also be excluded from the study.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Aspirin and MCDs
ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery.
ASA 325mg BID will be prescribed for a period of 6 weeks.
|
Other Names:
|
EXPERIMENTAL: Aspirin only
ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital.
ASA 325mg BID will be prescribed for a period of 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VTE/PE
Time Frame: 6 months
|
Using the MCS (Mobile Compression Systems) Mobile Pumps system for 10 days after surgery from hospital combined with 6 weeks of aspirin will prove superior to the use of 6 weeks of aspirin in the prophylaxis of VTE/PE in standard risk joint arthroplasty patients.
Efficacy will be measured in relation to previously published clinical trials with these agents and with previous patient cohorts at our institution.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cessation of anticoagulation therapy for any reason
Time Frame: 6 months
|
Patient reported data will be collected to capture this information.
|
6 months
|
Readmission to the hospital for any VTE event or surgical site complication in relation to VTE prophylaxis therapy
Time Frame: 6 months
|
Electronic Medical Records will be reviewed and patient reported data will be collected
|
6 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Embolism and Thrombosis
- Embolism
- Thrombosis
- Venous Thrombosis
- Thromboembolism
- Pulmonary Embolism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- 201608075
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PE - Pulmonary Thromboembolism
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
Suzhou Zenith Vascular Scitech Co., Ltd.Not yet recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismChina
-
Inari MedicalCompletedPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
Johannes Gutenberg University MainzBayer; Maastricht University; University of Bonn; Siemens Corporation, Corporate... and other collaboratorsRecruitingVenous Thromboembolism (VTE) | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)Germany
-
BayerJanssen Research & Development, LLCCompletedDeep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
-
Daiichi Sankyo, Inc.CompletedCancer | Venous Thromboembolism (VTE) | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)United States, Netherlands, Italy, Belgium, France, Hungary
-
Daiichi Sankyo, Inc.CompletedVenous Thrombosis | Thromboembolism | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)France, United States, Japan, Denmark, Italy, Russian Federation, Czechia, Germany, India, Israel, Philippines, Taiwan, Ukraine, Australia, Austria, China, Argentina, Belarus, Belgium, Brazil, Canada, Chile, Estonia, Hungary, Korea, Republic... and more
-
Alliance Foundation Trials, LLC.Patient-Centered Outcomes Research InstituteCompletedCancer | Venous Thromboembolism | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Blood ClotUnited States
-
Bayside HealthUnknown
Clinical Trials on Aspirin
-
The First Affiliated Hospital with Nanjing Medical...UnknownCoronary AtherosclerosisChina
-
Seoul National University HospitalCKD Pharmaceutical LimitedCompleted
-
Queen Mary University of LondonCancer Research UK; Barts and the London School of Medicine and DentistryCompletedProstate CancerUnited Kingdom
-
FANG HERecruitingPreeclampsia | Perinatal HaemorrhageChina
-
University of VigoRecruiting
-
Seoul National University HospitalCompletedCoronary Artery DiseaseKorea, Republic of
-
Seoul National University HospitalCompletedHealthyKorea, Republic of
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPulmonary Disease, Chronic ObstructiveUnited States
-
PLx PharmaCompletedDiabetes Mellitus, Type 2United States
-
BayerCompleted